(Reuters) - AbbVie Inc said on Thursday it expects sales of its flagship rheumatoid arthritis drug Humira to decline 37% this year due to competition from cheaper biosimilars in the United States, but ...

Sept 10 (Reuters) - UnitedHealth Group (UNH.N), opens new tab said on Tuesday it will remove AbbVie’s (ABBV.N), opens new tab blockbuster rheumatoid arthritis drug Humira from some of its lists of ...

Oct 20 (Reuters) - AbbVie (ABBV.N), opens new tab said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira in a head-to-head . AbbVie has been ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

In May 2025, the FDA approved numerous biosimilars as interchangeable with Stelara ® (ustekinumab) and Humira ® (adalimumab), bringing the total number of Stelara ® interchangeables to four, plus an ...

AbbVie stock outperformed S&P 500 with a +16% to 9.41% return since November 2023, despite Humira revenue declining 38% to $8.99 billion. Immunology drugs Skyrizi and Rinvoq grew over 50% ...

A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira, cutting out pharmacy benefit managers — controversial middlemen in the drug ...

A top California health plan is set to offer one of the world’s biggest-selling drugs for free in a bid to show the medicine can reach Americans affordably without going through the middlemen that ...